EP Patent

EP1485344A1 — Venlafaxine besylate

Assigned to Synthon BV · Expires 2004-12-15 · 21y expired

What this patent protects

The invention relates to a venlafaxine besylate compound, preferably crystalline venlafaxine besylate, to a pharmaceutical composition comprising said venlafaxine besylate compound and at least one pharmaceutically acceptable excipient, to a method for treating a venlafaxine-trea…

USPTO Abstract

The invention relates to a venlafaxine besylate compound, preferably crystalline venlafaxine besylate, to a pharmaceutical composition comprising said venlafaxine besylate compound and at least one pharmaceutically acceptable excipient, to a method for treating a venlafaxine-treatable disease or condition, which comprises administering to a patient in need thereof an effective amount of a venlafaxine besylate compound, and to a process for making a venlafaxine besylate composition, which comprises: mixing venlafaxine besylate and a molten fusible carrier to form a partially melted mass; and cooling said partially melted mass to form a solidified product.

Drugs covered by this patent

Patent Metadata

Patent number
EP1485344A1
Jurisdiction
EP
Classification
—
Expires
2004-12-15
Drug substance claim
No
Drug product claim
No
Assignee
Synthon BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.